



MAR 25 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Thomas Charles Boone, et al.

Serial No.: 10/666,480 Group Art Unit No.: 1654

Filed: September 18, 2003 Examiner: To Be Assigned

For: Peptides and Related Molecules that Modulate Nerve  
Growth Factor Activity

Docket No.: A-827

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Robert L. Sharp  
Attorney/Agent for Applicant(s)  
Registration No.: 45,609  
Phone: (805) 447-5992  
Date: March 23, 2004

**EXPRESS MAIL CERTIFICATE**

"Express Mail" label number: EV 351338201US Date of Deposit: March 23, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew

Printed Name

Signature

Please send all future correspondence to:

US Patent Operations/RLS  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799



Sheet 1 Of 1

Modified from PTO-1449

Atty. Docket No.

A-827

Serial No.

10/666.480

Applicant

Thomas Charles Boone, et al.

Filing Date

September 18, 2003

Group

1654

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	6,660,843	09/12/03	Feige et al.			
	A2						
	A3						
	A4						
	A5						
	A6						
	A7						
	A8						
	A9						
	A10						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES      NO
	B1	WO96/32478	17/10/96	PCT			X
	B2	WO97/34631	25/09/97	PCT			X
	B3	WO00/24782	04/05/00	PCT			X
	B4						
	B5						

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

	C1	Ramer, M.S., et al., Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment. Eur J Neurosci 11:837-846 (1999)
	C2	Ro, L.S., et al., Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Pain 79: 265-274 (1999)
	C3	
	C4	
	C5	
	C6	

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.